Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Aggressive treatment needed in Takayasu arteritis patients with severe ischaemic events

27 Aug 2020

Patients with Takayasu arteritis (TA) are at greater risk of experiencing severe ischaemic events (SIEs), which occur early in the disease, according to a study, adding that aggressive treatment can lead to a favourable prognosis in this population.

Fifty-two patients with at least one follow-up visit between 1988 and 2015 from three academic centres in Ontario, Canada, were included in this study. Diagnosis was based on American College of Rheumatology criteria, physician opinion, and vascular imaging.

SIEs were defined as cerebrovascular accident (CVA), acute coronary syndrome (ACS), ischaemic cardiomyopathy, ischaemic blindness, and ischaemic bowel or limb requiring surgery.

Of the included patients (mean age at time of diagnosis, 31 years) 51 (98 percent) were female and 22 (42 percent) were of European descent. Follow-up time was 6 years.

Fifteen TA patients (29 percent) experienced SIEs: five CVA, five ACS, one ischaemic cardiomyopathy, and four limb ischaemia. Of these, 13 (87 percent) occurred at or prior to diagnosis. Patients with SIE were more likely to initiate corticosteroid treatment in combination with immunosuppressants (p=0.04) and antiplatelet agents (p=0.004) compared to those without SIE.

Of note, outcomes including disease activity and dame scores were comparable between patients with and without SIE.

“TA is a rare large-vessel vasculitis that puts patients at high risk of developing SIEs,” the authors said. “Outcomes for TA patients with SIE are poorly understood.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.